B. Riley set a $10.00 target price on Amyris (NASDAQ:AMRS) in a report issued on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on AMRS. BidaskClub upgraded shares of Amyris from a buy rating to a strong-buy rating in a research report on Friday, May 4th. Zacks Investment Research cut shares of Amyris from a buy rating to a hold rating in a research report on Thursday, May 3rd. HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Amyris in a research report on Monday, April 2nd. Finally, ValuEngine cut shares of Amyris from a buy rating to a hold rating in a research report on Monday, April 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $9.13.

Shares of NASDAQ AMRS opened at $5.17 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 0.67 and a debt-to-equity ratio of -0.35. Amyris has a 52-week low of $1.86 and a 52-week high of $7.30. The company has a market capitalization of $254.90 million, a price-to-earnings ratio of -1.70 and a beta of 0.15.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($1.31). The business had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $24.12 million. During the same period in the prior year, the business posted ($0.13) EPS. The business’s revenue for the quarter was up 77.2% on a year-over-year basis. research analysts expect that Amyris will post -1.92 earnings per share for the current year.

In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the company’s stock in a transaction on Monday, May 7th. The shares were sold at an average price of $6.54, for a total value of $622,359.48. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 21.80% of the company’s stock.

Large investors have recently bought and sold shares of the company. Compagnie Lombard Odier SCmA boosted its stake in shares of Amyris by 60.0% in the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 39,000 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Amyris in the 4th quarter valued at $451,000. Crown Advisors Management Inc. bought a new stake in shares of Amyris in the 1st quarter valued at $669,000. B. Riley Financial Inc. bought a new stake in shares of Amyris in the 1st quarter valued at $294,000. Finally, Creative Planning bought a new stake in shares of Amyris in the 4th quarter valued at $188,000. 23.95% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.